| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.10.25 | Linzer KI-Startup Optimind automatisiert Landingpage-Optimierung mit selbstlernenden System | 1 | der brutkasten | ||
| 11.09.25 | Optimind Pharma Corp: Optimind Pharma to remain halted | 1 | Stockwatch | ||
| 11.09.25 | CSE Bulletin: Halted for Fundamental Change - Optimind Pharma Corp. (OMND) | 321 | Newsfile | Toronto, Ontario--(Newsfile Corp. - Le 11 septembre/September 2025) - Trading in the shares of Optimind Pharma Corp. (OMND) will remain halted pending receipt and review of acceptable documentation... ► Artikel lesen | |
| OPTIMIND PHARMA Aktie jetzt für 0€ handeln | |||||
| 08.09.25 | Optimind Pharma Corp.: Optimind Pharma Announces Definitive Agreement for Proposed Change of Business with InterviewDesk | 488 | Newsfile | Toronto, Ontario--(Newsfile Corp. - September 8, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") is pleased to announce that it has entered into a binding definitive share... ► Artikel lesen | |
| 05.09.25 | Optimind Pharma Corp: Optimind cancels Monjin acquisition | 1 | Stockwatch | ||
| 04.09.25 | Optimind Pharma Corp.: Optimind Pharma Announces Termination of Letter of Intent | 543 | Newsfile | Toronto, Ontario--(Newsfile Corp. - September 4, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that its previously announced non-binding letter of intent dated... ► Artikel lesen | |
| 25.03.25 | Optimind Pharma Corp.: Optimind Pharma Enters into Letter of Intent with Monjin to Acquire AI Business | 748 | Newsfile | Toronto, Ontario--(Newsfile Corp. - March 24, 2025) - Optimind Pharma Corp. (CSE: OMND) (the "Optimind" or the "Company") announces that it has entered into a non-binding letter of intent dated March... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 32,985 | +4,75 % | Novo Nordisk Aktie: Kommt jetzt der Konter der Bullen? | Um die katastrophalen Kursverluste der Novo Nordisk Aktie einschätzen zu können, muss man in den Juni 2024 schauen: Da erreichte der dänische Pharmatitel an der Börse in Kopenhagen bei mehr als 1.033... ► Artikel lesen | |
| AURORA CANNABIS | 3,140 | +4,32 % | Canadian LP Aurora Cannabis is now 'solely' a medical company | ||
| CANOPY GROWTH | 0,940 | +2,51 % | Is Canopy Growth Stock Going to $0? | ||
| BIOTEST | 31,800 | 0,00 % | Biotest erhält FDA-Zulassung | Summary: FDA lässt Fibrinogen-Produkt für den US-Markt zu Biotest entwickelt und produziert, Grifols vermarktet Markteinführung für 2026 geplant Pipeline gewinnt strategisch an Gewicht Biotest hat einen... ► Artikel lesen | |
| DIGICANN VENTURES | 0,004 | -12,50 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| SINOPHARM | 2,235 | -0,89 % | HSI Closes at 26,765, Up 175 pts; HSTI Closes at 5,260, Down 10 pts; HAIDILAO Up over 6%; HSBC HOLDINGS, TINGYI, SINOPHARM, TIME INTERCON, WANGUO GOLD GP Hit New Highs; Market Turnover Rises | ||
| CSPC PHARMA | 1,005 | -1,37 % | CSPC PHARMA (01093): VOLUNTARY ANNOUNCEMENT - EMICIZUMAB INJECTION (SYS6053) OBTAINS CLINICAL TRIAL APPROVAL IN CHINA | ||
| TONIX PHARMACEUTICALS | 12,000 | 0,00 % | Tonix Pharmaceuticals Holding Corp.: Tonix Pharmaceuticals Announces Uplisting from Nasdaq Capital Market to Nasdaq Global Select Market | BERKELEY HEIGHTS, N.J., March 03, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, today... ► Artikel lesen | |
| ORAMED PHARMACEUTICALS | 3,058 | +5,92 % | Dividendenbekanntmachungen (16.01.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ABBVIE INC US00287Y1091 1,73 USD 1,4902 EUR ABBVIE INC CDR CA00288K1084 0,2439 CAD 0,1512 EUR ALAMO GROUP INC US0113111076 0... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 141,45 | +0,11 % | Axsome Therapeutics auf Oppenheimer-Konferenz: Wachstumsstrategie im Fokus | ||
| ADASTRA | 0,086 | +0,58 % | Adastra Holdings Ltd.: Adastra Holdings Announces Agreement to Sell Assets and Resignation of Director | Langley, British Columbia--(Newsfile Corp. - March 2, 2026) - Adastra Holdings Ltd. (CSE: XTRX) (FSE: D2E0) ("Adastra" or the "Company") announces that Adastra Labs Inc. ("Adastra Labs"), a wholly-owned... ► Artikel lesen | |
| ALTIMMUNE | 3,709 | +3,69 % | What to Expect from Altimmune's Earnings | ||
| ACHIEVE LIFE SCIENCES | 3,765 | +0,94 % | Achieve Life Sciences: Entscheidet der 20. Juni über Leben und Tod? | Seit unseres Trading-Tipps im Juli letzten Jahres konnte die Aktie von Achieve Life Sciences zwischenzeitlich über +150% zulegen, korrigierte in den letzten Wochen aber wieder um mehr als 20%. Das Unternehmen... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 4,725 | +3,62 % | SELLAS Life Sciences Group, Inc.: SELLAS Life Sciences Provides Update on Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) | Contract Research Organization for the REGAL trial has informed the Company that 72 events have occurred in the trial as of December 26, 2025; SELLAS remains blinded to trial outcomesTiming of the... ► Artikel lesen | |
| CATALYST PHARMACEUTICALS | 20,650 | +0,29 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance | Full Year 2025 Total Revenues of $589.0 Million, Representing 19.8% Year-Over-Year Growth and Marking Another Year of Record Total Revenues Q4 2025 Total Revenues of $152.6 Million, Fueled by 18.3%... ► Artikel lesen |